1. Select a pharmaceutical random controlled trial (RTC) research article, published within the past 5 years.

2. Answer the following questions:
 What is the purpose of the study?
 Name the study design and analytic methods.
 List the study variables?
 How was this sample size determined?
 What were the age, gender, race, specific diagnostic criteria and socioeconomic status of the participants in this trial? Who was excluded?
 Did the sample size [change/stay the same/disappear]. What was your final sample size? How the people who dropped out compare on [measure of severity of the disorder]? How did the people who dropped out compare on [side effects]?
 How much more effective is this drug than [older, better-known drugs]?
 What was the clinical measure used for the outcome?
 Was the clinical outcome that was measured relevant to clients?
 How long has this drug been on the market?
 What is the data on the development of side effects; how long do they take to develop?
 What is the data on side effects that might be expected to diminish over time?
 Were measurements stopped prior to the point at which serious side effects develop?

3. Summarize the strengths and weaknesses of the research. This is your opinion as to the efficacy, safety & utility of this pharmaceutical agent for the intended population

Literature Critique: Lecanemab in Early Alzheimer’s Disease (the CLARITY AD Trial)

Article reviewed: van Dyck, C. H., Swanson, C. J., Aisen, P., et al. (2023). Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine, 388(1), 9–21.

Purpose of the Study

The CLARITY AD trial was designed to determine whether lecanemab, a humanized monoclonal antibody that targets soluble aggregated forms of amyloid-beta, could slow the clinical decline associated with early Alzheimer’s disease while also reducing measurable amyloid plaque burden in the brain. Unlike older Alzheimer’s medications, which only manage symptoms without altering the underlying disease process, lecanemab was developed under the “amyloid hypothesis,” the idea that clearing amyloid protein from the brain might actually slow the progression of the disease itself. The researchers wanted to know two things at once: did removing amyloid translate into a meaningful difference in how patients functioned day to day, and was the drug safe enough to justify long-term use in a population that is already medically vulnerable.

Study Design and Analytic Methods

This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial conducted at sites across North America, Europe, and Asia. Participants were randomly assigned in a 1:1 ratio to receive either lecanemab, dosed at 10 mg per kilogram of body weight by intravenous infusion every two weeks, or a matching placebo infusion, for a total of 18 months. After the double-blind phase ended, participants were eligible to enter an open-label extension in which everyone received active drug, allowing researchers to gather longer-term safety data and to compare outcomes between those who started treatment earlier versus later.

The primary analytic approach used a mixed-model repeated-measures analysis to estimate the adjusted mean change from baseline on the primary outcome measure at 18 months, comparing the lecanemab group to the placebo group. Secondary outcomes were analyzed similarly, with statistical testing performed in a pre-specified hierarchical order to control for multiple comparisons, meaning that a secondary endpoint was only considered statistically confirmed if the endpoints above it in the hierarchy also reached significance.

Study Variables

The independent variable was treatment assignment: lecanemab versus placebo. The primary dependent variable was the change from baseline to 18 months in the Clinical Dementia Rating–Sum of Boxes (CDR-SB), a scale that combines both cognitive and functional ratings across six domains, including memory, orientation, judgment, community affairs, home and hobbies, and personal care. Secondary dependent variables included the 14-item cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog14), the Alzheimer’s Disease Composite Score (ADCOMS), and the Alzheimer’s Disease Cooperative Study–Activities of Daily Living scale for mild cognitive impairment (ADCS-MCI-ADL). Biomarker variables included amyloid PET imaging (measured in centiloid units) and plasma biomarkers such as the amyloid-beta 42/40 ratio. Safety variables included the incidence of amyloid-related imaging abnormalities (ARIA), infusion-related reactions, and other adverse events tracked through MRI and routine clinical monitoring. Exploratory quality-of-life variables included the EQ-5D-5L and the Quality of Life in Alzheimer’s Disease (QOL-AD) scales, along with the Zarit Burden Interview, which measured the strain experienced by caregivers.

Sample Size Determination

The trial enrolled 1,795 participants, with 898 randomized to lecanemab and 897 to placebo. A sample of this size was chosen to provide adequate statistical power to detect a clinically meaningful difference in the CDR-SB between groups at 18 months, accounting for an expected rate of dropout over the course of the study. Because the CDR-SB is a relatively sensitive measure that changes gradually over time in early-stage disease, a large sample was needed to detect a treatment effect that, while real, was expected to be modest in absolute terms.

Participant Characteristics and Exclusions

Eligible participants were between 50 and 90 years of age and had a diagnosis of either mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia, corresponding to a CDR global score of 0.5 to 1.0 and a Mini-Mental State Examination score in the mild-impairment range. Critically, all participants also had to have confirmed evidence of amyloid pathology in the brain, established either through PET imaging or cerebrospinal fluid analysis, ensuring that everyone enrolled actually had the underlying pathology the drug was designed to target.

The trial enrolled participants from sites across North America, Europe, and the Asia-Pacific region, and roughly a quarter of participants identified as Hispanic or Latino, with smaller proportions identifying as Black or African American and Asian. As with many Alzheimer’s trials historically, the overall sample skewed toward white participants relative to the demographics of the broader population affected by Alzheimer’s disease in the United States, which has been raised as a limitation regarding how well the results generalize across racial and ethnic groups. Roughly half of participants were women, and the average age was in the early seventies, consistent with the typical age of onset for early symptomatic Alzheimer’s disease. Socioeconomic status was not a formal eligibility criterion, but participation in a trial requiring biweekly infusions, regular MRI scans, and frequent clinic visits inherently favors individuals with reliable transportation, flexible schedules, and access to academic medical centers, which may have skewed the sample toward more advantaged populations even without an explicit socioeconomic requirement.

Participants were excluded if they had any other significant neurological condition that could explain their cognitive symptoms, such as a prior stroke, other forms of dementia, or significant cerebrovascular disease visible on MRI. People taking anticoagulant medications or with a history of more than a small number of prior microhemorrhages were also excluded, given the known risk that anti-amyloid antibodies can increase the likelihood of brain bleeding (ARIA-H). Individuals with major psychiatric illness, contraindications to MRI, or other serious unstable medical conditions were excluded as well, since these would complicate both safety monitoring and interpretation of cognitive outcomes.

Sample Size Over Time, Dropouts, and Comparisons

The sample size did not stay perfectly constant over the 18-month trial; as with virtually all long-duration trials, some attrition occurred, though the great majority of randomized participants completed the double-blind period and contributed to the final efficacy analyses. The most informative dropout-related figures reported in the trial concern adverse-event-related discontinuation specifically: 6.9 percent of participants in the lecanemab group discontinued the study drug because of an adverse event, compared with 2.9 percent in the placebo group. This more than two-fold difference is almost entirely attributable to ARIA and infusion-related reactions, which were far more common in the active treatment arm.

The published trial report does not provide a detailed side-by-side comparison of baseline disease severity between participants who dropped out and those who completed the study, which is itself worth noting as a gap, since it leaves open the question of whether people with more advanced disease at baseline were more or less likely to discontinue. What is clearer is the side-effect comparison: those who dropped out in the lecanemab arm did so disproportionately because of ARIA-E (brain swelling, occurring in 12.6 percent of the lecanemab group versus 1.7 percent of placebo) and ARIA-H (microhemorrhages, occurring in 17.3 percent of the lecanemab group versus 9.0 percent of placebo), as well as infusion-related reactions (26.4 percent versus 7.4 percent). In other words, people who left the study early in the treatment arm were, by definition, more likely to be among those experiencing these imaging-based and infusion-related side effects, since adverse events were the stated reason for discontinuation in that subgroup.

Effectiveness Compared with Older Drugs

The headline efficacy finding was that participants receiving lecanemab declined by 1.21 points on the CDR-SB over 18 months, compared with 1.66 points for those receiving placebo, representing a 27 percent slowing in the rate of decline, equivalent to an absolute difference of 0.45 points on an 18-point scale. This places lecanemab in a fundamentally different category from older Alzheimer’s medications such as donepezil, rivastigmine, galantamine, and memantine, none of which have ever been shown to alter the underlying trajectory of decline; those drugs offer temporary symptomatic improvement in cognition but do not change the disease’s course, and their benefits typically plateau or fade within months. Lecanemab, by contrast, is the first drug in this class to demonstrate a statistically significant slowing of decline on a primary clinical endpoint alongside biomarker evidence of amyloid clearance, placing it in the same general category as donanemab, another anti-amyloid antibody that showed a similar magnitude of benefit in its own pivotal trial. Compared with aducanumab, an earlier anti-amyloid antibody whose approval was highly controversial due to conflicting results between its two pivotal trials, lecanemab’s results were more consistent and are generally regarded as more robust.

Clinical Outcome Measure and Its Relevance

The primary clinical outcome, the CDR-SB, is widely used precisely because it blends cognitive performance with real-world functional status, drawing on structured interviews with both the patient and a caregiver who knows the patient well. In that sense, it is directly relevant to the day-to-day experience of patients and families, since it reflects not just test scores but whether someone can still manage their finances, participate in hobbies, or care for themselves. That said, there is ongoing debate within the field about whether a 0.45-point difference on this 18-point scale represents a difference that a patient or caregiver would actually notice in daily life, since estimates of the “minimal clinically important difference” for the CDR-SB vary and some fall close to or above the size of the observed effect. This tension, between a statistically significant result and a result that feels meaningful at the bedside, is one of the most important interpretive questions raised by this trial.

Drug Market History and Side Effect Timeline

Lecanemab, marketed as Leqembi, received accelerated approval from the FDA in January 2023 and full traditional approval in July 2023, meaning that as of this writing it has been commercially available for roughly three years. This relatively short market history means that real-world safety data are still accumulating alongside the trial data.

Regarding the timeline of side effects, ARIA-E typically develops early in treatment, with the large majority of cases occurring within the first three to six months and most resolving within about four months of detection. Infusion-related reactions follow an even more front-loaded pattern, with the majority occurring during the very first infusion. ARIA-H (microhemorrhages and related findings) follows a somewhat broader window but is also concentrated in the earlier months of treatment and is strongly associated with having one or two copies of the ApoE ε4 gene variant, with homozygous carriers facing substantially higher risk than non-carriers.

Side Effects Expected to Diminish Over Time

Several side effects appear to diminish with continued treatment. Infusion-related reactions, which are most common on the first dose, become substantially less frequent with subsequent infusions, particularly when premedication strategies are used. Longer-term extension data also suggest that once a patient has gone six months without developing ARIA, their subsequent risk of developing new ARIA drops to a level close to that seen in the placebo group, suggesting that the period of highest vigilance is concentrated in the early months of treatment rather than persisting indefinitely.

Were Measurements Stopped Before Serious Side Effects Could Develop?

This is one of the more important limitations of the trial. The core double-blind period lasted only 18 months, which, while long by clinical trial standards, is short relative to the multi-year course of Alzheimer’s disease and the multi-year duration that patients might realistically remain on this medication. Rare but serious events, including fatal brain hemorrhages, have since been reported in lecanemab-treated patients, particularly those who were also receiving blood thinners or clot-dissolving medications for unrelated medical emergencies, scenarios that may not have been fully captured within an 18-month, carefully monitored trial population that excluded most anticoagulant users at baseline. This raises a legitimate question about whether the trial’s duration and exclusion criteria were sufficient to detect the full range of serious adverse events that might emerge over the longer periods of real-world use, in more medically complex populations, that this drug is now being prescribed to.

Summary: Strengths, Weaknesses, and Overall Assessment

The strengths of this trial are considerable. It is large, multicenter, rigorously randomized and double-blinded, and it required biomarker confirmation of amyloid pathology in every participant, ensuring that the population studied actually had the disease process the drug was designed to address. The convergence of clinical, functional, quality-of-life, and biomarker results all pointing in the same direction lends credibility to the finding that this drug does something biologically real, not just statistically detectable.

At the same time, the weaknesses are significant enough that they should shape how this drug is used. The absolute clinical benefit is modest and sits close to thresholds debated as the minimum a patient might actually notice. The safety profile, particularly the substantially elevated rates of ARIA-E, ARIA-H, and infusion reactions, requires intensive monitoring infrastructure, including repeated MRIs and genetic testing for ApoE status, that many healthcare systems are not yet equipped to provide at scale. The population studied was healthier, more amyloid-confirmed, and less racially diverse than the broader population of people living with Alzheimer’s disease, raising questions about generalizability. And the 18-month window, while informative, leaves real uncertainty about what happens with years of continued use.

In my view, lecanemab represents a genuine, if incremental, step forward, the first drug to convincingly demonstrate disease modification on a clinical endpoint in Alzheimer’s disease. However, I would not characterise it as a breakthrough that dramatically changes the trajectory for most patients. Its appropriate use depends heavily on careful patient selection, especially with regard to ApoE4 status, realistic communication with patients and families about the size of the expected benefit, and continued long-term safety surveillance through registries and extension studies, since the pivotal trial alone cannot answer every question that matters for a medication intended to be used for years in an aging, medically complex population.

Reference

van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., Froelich, L., Katayama, S., Sabbagh, M., Vellas, B., Watson, D., Dhadda, S., Irizarry, M., Kramer, L. D., & Iwatsubo, T. (2023). Lecanemab in early Alzheimer’s disease. New England Journal of Medicine, 388(1), 9–21.

For a custom paper on the above topic or any other topic, place your order now!
What Awaits you:
On-time delivery guarantee
Masters and PhD-level writers
Automatic plagiarism check
100% Privacy and Confidentiality
High Quality custom-written papers